Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Chin Hur

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2819-7576; OpenAlex author ID A5055200350; NIH RePORTER profile ID 7040249. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 8)
Trials
0
Grants
2
Labs led
3
Collaborators
38
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper, 1 grant · 2022: 3 papers, 1 grant · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 18

  1. Toward Clinically Actionable Prediction of Recurrence and Metastatic Progression in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Last author DOI 10.1200/cci-26-00200↗
  2. Enhancing EHR-based pancreatic cancer prediction with LLM-derived embeddings. Co-author DOI 10.1038/s41746-025-01869-8↗
  3. Structured deep embedding model to generate composite clinical indices from electronic health records for early detection of pancreatic cancer. Co-author DOI 10.1016/j.patter.2022.100636↗
  4. Quantifying the potential benefits of early detection for pancreatic cancer through a counterfactual simulation modeling analysis. Last author DOI 10.1038/s41598-023-46751-3↗
  5. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Last author DOI 10.1002/cnr2.1565↗
  6. Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer. Co-author DOI 10.1016/j.jbi.2022.104095↗
  7. Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model. Co-author DOI 10.1016/j.pan.2022.05.003↗
  8. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001835↗
  9. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.03.035↗
  10. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Co-author DOI 10.1097/md.0000000000018082↗
  11. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. Co-author DOI 10.1371/journal.pone.0215409↗
  12. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Last author DOI 10.1634/theoncologist.2018-0114↗
  13. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Last author DOI 10.1002/cam4.1277↗
  14. Patterns and predictors of end-of-life care in older patients with pancreatic cancer. Last author DOI 10.1002/cam4.1861↗
  15. Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Co-author DOI 10.1016/j.pan.2018.07.009↗
  16. Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. Co-author DOI 10.1097/mpa.0000000000000587↗
  17. Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model. Last author DOI 10.1016/j.ebiom.2015.11.005↗
  18. Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Last author DOI 10.1148/radiol.14141282↗

Grants 2

  1. Domain-Knowledge Informed Deep Learning for Early Detection of Pancreatic Cancer R21CA265400↗
  2. Optimizing the Treatment of Pancreatic Adenocarcinoma R01CA212086↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chung Yin Kong · 10 shared papers, 1 shared grant, 2015–2022 · strength 1.42
  2. Nicholas P. Tatonetti · 3 shared papers, 1 shared grant, 2022–2025 · strength 1.32
  3. Jiheum Park · 5 shared papers, 2022–2025 · strength 1.00
  4. Angela C. Tramontano · 9 shared papers, 2015–2020 · strength 0.77
  5. Pari V. Pandharipande · 8 shared papers, 2015–2022 · strength 0.69
  6. Gulam Abbas Manji · 2 shared papers, 2022–2026 · strength 0.45
  7. Mary Linton B. Peters · 3 shared papers, 2018–2022 · strength 0.35
  8. Myles A. Ingram · 2 shared papers, 2022 · strength 0.31
  9. Liyuan Gong · 1 shared paper, 2026 · strength 0.30
  10. Ryan David Nipp · 3 shared papers, 2018–2019 · strength 0.29
  11. Fay Kastrinos · 2 shared papers, 2021–2022 · strength 0.26
  12. Carlos F. Fernandez-del Castillo · 2 shared papers, 2019–2020 · strength 0.19
  13. Cristina Rosa Ferrone · 2 shared papers, 2019–2020 · strength 0.19
  14. Deborah Schrag · 2 shared papers, 2018–2019 · strength 0.17
  15. William Robert Brugge · 3 shared papers, 2015–2016 · strength 0.16
  16. Susan Elaine Bates · 1 shared paper, 2022 · strength 0.15
  17. Shria Kumar · 1 shared paper, 2021 · strength 0.11
  18. Marcia Irene Canto · 1 shared paper, 2021 · strength 0.11
  19. Bryson W. Katona · 1 shared paper, 2021 · strength 0.11
  20. Randall E. Brand · 1 shared paper, 2021 · strength 0.11
  21. Michael Goggins · 1 shared paper, 2021 · strength 0.11
  22. Anil K. Rustgi · 1 shared paper, 2021 · strength 0.11
  23. Zhi Ven Fong · 1 shared paper, 2020 · strength 0.11
  24. Andrew Louis Warshaw · 1 shared paper, 2020 · strength 0.11
  25. Naomi M. Sell · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.